

**Cadbury plc**  
**CBRY - LN / CBY - NYSE**  
 London, UK

<b>Capitalization</b> <i>(in millions, except per share data)</i>		2/16/10
	US\$/UK =	\$ 1.58

  

Balance Sheet as of	12/31/09	ADRs*
Common Shares	1,374	343.4
Options (a)	14	3.5
Diluted shares before consolidation	1,388	347
Market Price	8.42	\$ 53.12
Equity Market Capitalization	£11,685 pounds	\$ 18,432
Plus: Debt	1,375	2,172
Less: Cash & equivalents	-	-
Less: Short-term investments	-	-
Less: associates/min int	(9)	(14)
Total Enterprise Value	£13,051	\$ 20,617

\*1 ADR = 4 ord shares \$ 53.12

	High	Low		
Ord Shares 52-Week Trading Range	8.50	4.84	\$ 56.34	\$ 21.10

**LTM Leverage Statistics**

Net Debt/EBITDA	1.6
EBITDA/Interest Expense	8.3
Net Debt/TC	10.5

Dividend	per share	£0.165
	yld	2.0%

LTM 6/30/09	Multiple
Revenues	5,711 2.3
EBITDA	883 14.8
EPS	£0.33 25.9

- (a) Uses treasury method.
- (b) After-tax payments to buy out options holders at Private Market Value.
- (c) March 2003 purchase of Adam's from Pfizer for \$4.2bn
- (d) May 13, 2005 Acquired Green & Blacks (private; organic chocolate company with 22.4 million GBP in sales). UK
- (e) Pro forma for sale of European Beverages business divested on February 2, 2006 and acquisition of Dr Pepper Seven Up Bottling Group (announced 4/25/06).
- (f) Pro forma for spin-off of DPSG.
- (g) Includes sale of Schweppes Australia to Asahi Breweries on 4/3/09 for 550m GBP.

Pension assets	£ 2,269
Present value of future obligations	(2,527)
Underfunded amount	-£ 258
Discount rate	6.1%
Rate of asset returns	6.2%
Rate of salary increases	3.7%

ROIC	23%
ROE	11%

**Financial Data (in millions of pounds sterling)** 53 weeks

FYE 12/31	2003 (c)	2004 (d)	2005 (d)(e)	2006 (e)	Pro Forma 2007 (f)	Pro Forma 2008 (f)	2009 (g)	2010E	2011P	2012P	2013P
Net Revenues	£ 6,441	£ 6,085	£ 6,432	£ 7,427	£ 4,699	£ 5,384	£ 5,975	£ 6,305	£ 6,659	£ 7,033	£ 7,428
% Growth		-5.5%	5.7%	15.5%	-36.7%	14.6%	11.0%	5.5%	5.6%	5.6%	5.6%
EBITDA	1,265	1,146	1,210	1,343	641	830	1,018	1,141	1,263	1,366	1,474
Margin	19.6%	18.8%	18.8%	18.1%	13.6%	15.4%	17.0%	18.1%	19.0%	19.4%	19.8%
EBIT	1,052	954	1,025	1,073	473	638	808	919	1,030	1,121	1,216
Margin	16.3%	15.7%	15.9%	14.4%	10.1%	11.8%	13.5%	14.6%	15.5%	15.9%	16.4%
EPS from Continuing Ops	£ 0.32	£ 0.27	£ 0.30	£ 0.31	£ 0.23	£ 0.30	£ 0.38	£ 0.44	£ 0.51	£ 0.56	£ 0.63
% Growth		-14.5%	8.9%	5.2%	-25.8%	28.7%	26.4%	17.8%	14.4%	11.2%	11.1%
EBITDA Multiple					20.4	15.7	12.8	11.4	10.3	9.6	8.9
P/E Multiple				27.0	36.4	28.3	22.4	19.0	16.6	14.9	13.4

**Private Market Value Analysis**

	2003	2004	2005	2006	2007	2008	2009	2010E	2011P	2012P	2013P
<b>Americas</b>											
Revenues	871	1,093 25%	1,228 12%	1,330 8%	1,372 3%	1,631 19%	1,826 12%	1,954 7%	2,092 7%	2,234 7%	2,380 7%
EBITDA	121 14%	171 16%	203 17%	244 18%	272 20%	363 22%	426 23%	465 24%	504 24%	543 24%	584 24%
Valuation Multiple	14	14	14	14	14	14	14	14	14	14	14
Value	1,694	2,394	2,842	3,416	3,808	5,082	5,960	6,510	7,058	7,605	8,176
<b>BIMA</b>											
Revenues				1,500	1,579 5%	1,645 4%	1,820 11%	1,906 5%	1,999 5%	2,097 5%	2,202 5%
EBITDA				245 16%	215 14%	239 15%	306 17%	332 17%	361 18%	389 18%	418 19%
Valuation Multiple				12	12	12	12	12	12	12	12
Value				2,940	2,580	2,868	3,672	3,988	4,333	4,672	5,020
<b>Europe</b>											
Revenues				818	879 7%	1,097 25%	1,117 2%	1,151 3%	1,185 3%	1,221 3%	1,257 3%
EBITDA				113 14%	108 12%	148 13%	157 14%	184 16%	208 18%	220 18%	233 18%
Valuation Multiple				12	12	12	12	12	12	12	12
Value				1,356	1,296	1,776	1,879	2,212	2,491	2,639	2,794
<b>Asia Pacific</b>											
Revenues	937	1,050 12%	1,157 10%	1,205 4%	860 -29%	1,002 17%	1,204 20%	1,286 7%	1,376 7%	1,473 7%	1,580 7%
EBITDA	158 17%	167 16%	192 17%	201 17%	144 17%	172 17%	224 19%	243 19%	264 19%	287 19%	313 19%
Valuation Multiple	14	14	14	14	14	14	14	14	14	14	14
Value	2,212	2,338	2,688	2,814	2,016	2,408	3,134	3,405	3,698	4,021	4,379
<b>Central</b>											
Revenues	10	33	35	36	22	29	35	37	40	43	46
EBITDA	(123)	(130)	(149)	(139)	(98)	(92)	(93)	(84)	(74)	(74)	(74)
Valuation Multiple	12	12	12	12	12	12	12	12	12	12	12
Value	(1,476)	(1,560)	(1,788)	(1,668)	(1,176)	(1,104)	(1,116)	(1,008)	(888)	(888)	(888)
Total Private Market Value					8,524	11,030	13,530	15,107	16,692	18,050	19,481
Less: Net debt					(1,881)	(1,974)	(1,376)	(1,214)	(981)	(597)	(142)
Less: Options Payments (b)					-	(41)	(91)	(120)	(151)	(181)	(215)
Plus: Investment in associates					9	9	9	9	9	9	9
Equity Private Market Value					6,652	9,024	12,072	13,782	15,569	17,281	19,136
Shares Outstanding					1,345	1,345	1,372	1,372	1,372	1,372	1,372
PMV per share					£ 4.95	£ 6.71	£ 8.80	£ 10.05	£ 11.35	£ 12.60	£ 13.95
Current Market - Discount to PMV					-70.2%	-25.5%	4.3%	16.2%	25.8%	33.2%	39.6%

PMV per ADR (US \$)	\$ 42	\$ 56	\$ 63	\$ 72	\$ 80	\$ 88
---------------------	-------	-------	-------	-------	-------	-------

CAPEX	273	259	280	384	316	427	317	310	327	284	299
-------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

'08-'13	
Total	CAGR
£ 33,399	6.6%
6,262	12.2%
5,093	13.8%
£ 2.52	16.1%
2,523	10.0%
1,808	11.8%
1,002	2.8%
1,332	9.5%
1,332	12.7%